# Individual Rollout Analysis

Models: deepseek-chat, gpt-4o-mini, qwen-plus · 100 trials completed by all.

## Summary

Two cohorts are reported separately, because "all models got it wrong" is ambiguous once a model can abstain.

- **Shared false belief (9 trials)** — every model committed to a label and every model was wrong. Ground truth: {'FAILURE': 3, 'SUCCESS': 6}. Phases: {'PHASE1': 3, 'PHASE2': 3, 'PHASE3': 3}.
- **No correct answer (26 trials)** — S6 scored 0.0 for all models, which also catches the 17 trials where at least one model declined to predict. Ground truth: {'FAILURE': 7, 'SUCCESS': 19}. Phases: {'PHASE1': 10, 'PHASE2': 10, 'PHASE3': 6}.

An abstention is not a false belief, so the deep-dive below covers the first cohort; the second is listed for completeness.

- 6 of 9 shared-false-belief trials are SUCCESS trials the models called FAILURE-ward — the same lean the cross-model report measures.
- 9 of 9 drew the *same* wrong label from every model, so these are a shared belief rather than three independent errors.
- 1 were unanimous, confident (≥ 0.7) **and** backed by non-zero trial recall: `NCT03033524` (conf 0.82, S1 recall 0.33). These are the rows where a model demonstrably knew something about the trial and still contradicted the registry — the only profile that is evidence about the label rather than about the model's prior. Worth re-checking against ClinicalTrials.gov.

## Universally-Wrong Trials (shared false belief)


### Trial 1: NCT02442674

**Ground truth (`label`):** FAILURE  
**Phase:** PHASE3  
**Indication:** Hyponatremia  
**Sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.  
**Drug:** Tolvaptan  
**Title:** A Trial of Tolvaptan in Children and Adolescent Subjects With Euvolemic and Hypervolemic Hyponatremia

| Step | deepseek-chat | gpt-4o-mini | qwen-plus |
|---|---|---|---|
| S1 Trial Recall | 0.00 | 0.00 | 1.00 |
| S2 Reference Class | 0.33 | 1.00 | 1.00 |
| S3 Base Rate | 1.00 | 0.50 | 1.00 |
| S4 Success Criteria | 1.00 | 1.00 | 1.00 |
| S5 Risk Factors | 0.75 | 0.70 | 1.00 |
| S6 Prediction | 0.00 WRONG (SUCCESS) | 0.00 WRONG (SUCCESS) | 0.00 WRONG (SUCCESS) |

**deepseek-chat reasoning:**

*S5 Risk Factors (first 200 words):*

```
I'll frame these as risks inherent to this type of trial (pediatric tolvaptan in euvolemic/hypervolemic hyponatremia), using the title and general knowledge of tolvaptan and pediatric drug development. I'll flag where my reasoning is inference rather than confirmed fact. --- **RISK: Safety — hepatic injury / liver enzyme elevation** - APPLIES_BECAUSE: Tolvaptan carries a known hepatotoxicity signal in adults, which is why its use in autosomal dominant polycystic kidney disease (ADPKD) comes with a boxed warning and a restricted REMS-like monitoring program, and why hepatic (cirrhosis) use has been limited by liver-safety concerns. A pediatric trial would need to demonstrate this signal is not excessive in children, and any imbalance in transaminase elevations could halt or fail the study. This is arguably the most trial-threatening risk for tolvaptan specifically. - LIKELIHOOD: MEDIUM (the signal is real but dose- and population-dependent; pediatric exposure may differ). --- **RISK: Safety — overly rapid serum sodium correction / osmotic demyelination syndrome (ODS)** - APPLIES_BECAUSE: The therapeutic goal is to raise serum sodium, but over-correction risks ODS, a rare but catastrophic neurologic injury. In pediatric patients, especially smaller children and those with chronic hyponatremia, the margin for safe correction rate is narrow, and any ODS ...
```

*S6 Prediction (full):*

```
PREDICTION: SUCCESS
CONFIDENCE: 0.55
KEY_REASON: Tolvaptan's V2-antagonist mechanism reliably raises serum sodium and has already succeeded on this endpoint in adults, so a pediatric trial is likely to show a sodium benefit — but my confidence is only moderate because I have no verified outcome data for NCT02442674 and pediatric enrollment, dosing, and safety (especially hepatic and over-correction risks) could still produce a null or failed result.
```

**gpt-4o-mini reasoning:**

*S5 Risk Factors (first 200 words):*

```
1. **RISK: Efficacy Concerns** **APPLIES_BECAUSE:** There may be insufficient evidence from earlier trials or Phase 2 studies to support the effectiveness of Tolvaptan in children and adolescents with hyponatremia. If the treatment does not demonstrate a significant improvement in serum sodium levels or other clinical outcomes compared to the control, it could lead to trial failure. **LIKELIHOOD:** MEDIUM 2. **RISK: Safety Signals** **APPLIES_BECAUSE:** Safety concerns might arise during the trial, particularly since the study population includes children and adolescents, who may have different responses to medication than adults. Any adverse events or significant side effects could halt the trial or lead to regulatory scrutiny. **LIKELIHOOD:** MEDIUM 3. **RISK: Enrollment Challenges** **APPLIES_BECAUSE:** Enrolling a sufficient number of eligible pediatric subjects with euvolemic and hypervolemic hyponatremia could be difficult due to the relatively low prevalence of these conditions in children. Failing to meet enrollment targets could result in insufficient power to draw meaningful conclusions. **LIKELIHOOD:** HIGH 4. **RISK: Trial Design Limitations** **APPLIES_BECAUSE:** If the trial design does not adequately control for confounding variables or lacks proper blinding and randomization, the results may be biased, leading to inconclusive or misleading outcomes. This could undermine the validity of the findings. **LIKELIHOOD:** MEDIUM 5. **RISK: ...
```

*S6 Prediction (full):*

```
PREDICTION: SUCCESS  
CONFIDENCE: 0.65  
KEY_REASON: The prior efficacy of Tolvaptan in treating hyponatremia in adult populations and the growing understanding of its safety profile in this context suggest a favorable outcome in the pediatric population as well.
```

**qwen-plus reasoning:**

*S5 Risk Factors (first 200 words):*

```
RISK: Inadequate safety database in pediatric populations APPLIES_BECAUSE: Tolvaptan carries FDA black box warnings for hepatotoxicity (based on adult trials), and children may exhibit different pharmacokinetics, metabolism (e.g., CYP3A4 ontogeny), or susceptibility to liver injury; a single serious hepatic adverse event or pattern of transaminase elevations in this age group could halt enrollment or lead to regulatory non-approval despite efficacy. LIKELIHOOD: MEDIUM RISK: Insufficient enrollment or high discontinuation rate APPLIES_BECAUSE: Hyponatremia in children is relatively rare, often acute and hospital-based, with heterogeneous etiologies (e.g., SIADH, heart failure, cirrhosis — all uncommon in pediatrics); recruiting sufficient adolescents/children meeting strict euvolemic/hypervolemic criteria across sites would be challenging, and off-label alternatives or clinical caution may limit consent. LIKELIHOOD: HIGH RISK: Lack of clinically meaningful efficacy signal APPLIES_BECAUSE: Pediatric hyponatremia frequently resolves spontaneously or with fluid restriction; demonstrating a statistically *and* clinically significant treatment effect over placebo—especially on a sodium endpoint with high biological variability and influence from concomitant interventions (e.g., IV fluids, diuretics)—is difficult; adult effect sizes may not extrapolate reliably to developing physiology. LIKELIHOOD: MEDIUM RISK: Regulatory rejection due to inadequate risk-benefit assessment APPLIES_BECAUSE: FDA and EMA require compelling evidence that benefits outweigh risks in children, particularly for a drug with known ...
```

*S6 Prediction (full):*

```
PREDICTION: SUCCESS  
CONFIDENCE: 0.75  
KEY_REASON: The trial successfully demonstrated statistically significant and clinically relevant increases in serum sodium with tolvaptan versus placebo in children and adolescents, leading to FDA approval of tolvaptan for pediatric euvolemic and hypervolemic hyponatremia in 2021 — a fact consistent with public regulatory records and post-hoc knowledge of the outcome.
```

**Failure signature:** all 3 committed models said SUCCESS on a FAILURE trial; mean S1 recall 0.33; mean stated confidence 0.65

---

### Trial 2: NCT02521233

**Ground truth (`label`):** FAILURE  
**Phase:** PHASE3  
**Indication:** Essential Arterial Hypertension  
**Sponsor:** EMS  
**Drug:** Candesartan + Chlorthalidone (8mg+12,5mg)  
**Title:** Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control

| Step | deepseek-chat | gpt-4o-mini | qwen-plus |
|---|---|---|---|
| S1 Trial Recall | 0.00 | 0.00 | 0.00 |
| S2 Reference Class | 0.00 | 1.00 | 0.33 |
| S3 Base Rate | 1.00 | 1.00 | 0.50 |
| S4 Success Criteria | 0.70 | 0.70 | 0.70 |
| S5 Risk Factors | 0.80 | 0.50 | 0.80 |
| S6 Prediction | 0.00 WRONG (SUCCESS) | 0.00 WRONG (SUCCESS) | 0.00 WRONG (SUCCESS) |

**deepseek-chat reasoning:**

*S5 Risk Factors (first 200 words):*

```
I should restate my standing caveat: I don't actually know this trial's registered design, population, comparator, or results. The risks below are inferred from the drug combination (candesartan + chlorthalidone) and the indication (essential hypertension) — they are plausible failure modes, not documented facts about NCT02521233. **1. RISK: Comparator choice undercuts the efficacy claim** - APPLIES_BECAUSE: The trial's scientific value hinges on what candesartan + chlorthalidone is compared against. If the comparator is a weak or easily-beaten arm, a win is uninformative; if it's a potent active comparator (e.g., an ARB + HCTZ or an ARB + amlodipine regimen), the combination may fail to show superiority even if it works. The chlorthalidone-vs-HCTZ question is genuinely contested, so a null or ambiguous result is a real possibility. - LIKELIHOOD: HIGH **2. RISK: Failure to show a meaningful BP difference (efficacy dilution)** - APPLIES_BECAUSE: Both candesartan and chlorthalidone are well-established and effective individually, so the incremental benefit of combining them (rather than using either alone) may be modest or within measurement noise. BP endpoints have known variability (office vs. ABPM, visit-to-visit), and if the trial relies on office BP alone without ABPM, it may lack sensitivity to detect a real but small ...
```

*S6 Prediction (full):*

```
PREDICTION: SUCCESS
CONFIDENCE: 0.35
KEY_REASON: Despite my earlier base-rate reasoning that ARB-plus-diuretic hypertension trials in a mature indication tend to succeed, I have no actual recall of this trial's design, comparator, or results, so this prediction is close to a coin flip and is driven mainly by the favorable class-level base rate rather than any specific knowledge of NCT02521233.
```

**gpt-4o-mini reasoning:**

*S5 Risk Factors (first 200 words):*

```
Here are some key risk factors that could cause the trial NCT02521233 to fail, ordered from most to least concerning: 1. **RISK: Efficacy Concerns** - **APPLIES_BECAUSE:** There may be insufficient evidence from earlier phases or existing literature to support the combined efficacy of Candesartan and Chlorthalidone in significantly lowering blood pressure compared to an alternative treatment or placebo. If the drugs do not demonstrate a statistically significant reduction in blood pressure, the trial would be deemed a failure. - **LIKELIHOOD:** HIGH 2. **RISK: Safety Signals** - **APPLIES_BECAUSE:** If there are unexpected adverse events or safety concerns that arise during the trial, especially if they were not evident in previous studies, this could lead to early termination of the trial due to safety concerns. The combination of medications may produce unforeseen side effects affecting patient safety. - **LIKELIHOOD:** MEDIUM 3. **RISK: Enrollment Challenges** - **APPLIES_BECAUSE:** Difficulty in enrolling a sufficient number of eligible participants can hinder the trial's ability to achieve statistical power. If sites struggle to recruit patients with essential hypertension who meet the inclusion criteria, it could delay or even prevent the successful completion of the trial. - **LIKELIHOOD:** MEDIUM 4. **RISK: Regulatory Issues** - **APPLIES_BECAUSE:** Any failure to ...
```

*S6 Prediction (full):*

```
PREDICTION: SUCCESS  
CONFIDENCE: 0.65  
KEY_REASON: The combination of Candesartan and Chlorthalidone is based on established mechanisms with previous evidence showing that such combinations can effectively reduce blood pressure in patients with essential hypertension.
```

**qwen-plus reasoning:**

*S5 Risk Factors (first 200 words):*

```
- RISK: Inadequate BP-lowering efficacy relative to comparator APPLIES_BECAUSE: This trial evaluates candesartan + chlorthalidone for essential hypertension control — a setting where both agents are already approved as monotherapies and in other combinations; demonstrating *incremental* or *superior* efficacy (e.g., vs. candesartan alone or standard care) is challenging due to ceiling effects, high placebo response, and inter-individual BP variability. LIKELIHOOD: MEDIUM - RISK: Safety/tolerability issues leading to high dropout or regulatory concern APPLIES_BECAUSE: Chlorthalidone carries known risks of hypokalemia, hyponatremia, hyperuricemia, and glucose intolerance; combining it with an ARB may amplify risks like hyperkalemia (especially in older or renally impaired patients) or symptomatic hypotension. Hypertension trials often fail primary endpoints if safety-driven discontinuations bias efficacy estimates or trigger early termination. LIKELIHOOD: MEDIUM - RISK: Poor enrollment or high attrition APPLIES_BECAUSE: As a later-stage trial evaluating a combination of two generic, widely available antihypertensives, recruitment may suffer from lack of novelty, patient preference for established regimens, and competition from numerous active hypertension trials — especially given the large existing treatment landscape and low unmet need in mild-moderate essential hypertension. LIKELIHOOD: MEDIUM - RISK: Suboptimal trial design (e.g., inappropriate control arm, insufficient power, short duration) APPLIES_BECAUSE: Without access to the protocol, key ...
```

*S6 Prediction (full):*

```
PREDICTION: SUCCESS  
CONFIDENCE: 0.75  
KEY_REASON: ARB–thiazide-like diuretic combinations have a well-established mechanistic synergy and consistent BP-lowering efficacy in Phase 3 hypertension trials, making primary endpoint achievement highly probable for a well-conducted study of this design.
```

**Failure signature:** all 3 committed models said SUCCESS on a FAILURE trial; no trial-specific recall (S1=0.00); mean stated confidence 0.58

---

### Trial 3: NCT02762760

**Ground truth (`label`):** SUCCESS  
**Phase:** PHASE1  
**Indication:** Osteoarthritis of the Hand  
**Sponsor:** Ampio Pharmaceuticals. Inc.  
**Drug:** AMPION™  
**Title:** AP-011 Study to Evaluate the Safety of a Single Intra-articular Injection of Ampion™ for Arthritis of the Basal Thumb Joint

| Step | deepseek-chat | gpt-4o-mini | qwen-plus |
|---|---|---|---|
| S1 Trial Recall | 0.00 | 0.00 | 1.00 |
| S2 Reference Class | 0.00 | 1.00 | 0.00 |
| S3 Base Rate | 0.00 | 0.00 | 0.00 |
| S4 Success Criteria | 0.30 | 0.30 | 0.30 |
| S5 Risk Factors | 0.80 | 0.80 | 0.80 |
| S6 Prediction | 0.00 WRONG (FAILURE) | 0.00 WRONG (FAILURE) | 0.00 WRONG (FAILURE) |

**deepseek-chat reasoning:**

*S5 Risk Factors (first 200 words):*

```
RISK: Efficacy failure / no durable clinical benefit over control APPLIES_BECAUSE: Ampion is a biologic (amniotic-fluid-derived) injected intra-articularly for basal thumb OA. The intra-articular OA field has a long history of promising early signals that fail to replicate — steroids, HA, PRP, and growth-factor products all show modest, often transient benefit driven heavily by placebo response in injection trials. The basal thumb (CMC) joint is small, non-weight-bearing, and has a high placebo response rate, making a true drug effect hard to detect. If this study has any efficacy component, a null or non-durable result is the single most probable reason for failure. LIKELIHOOD: HIGH RISK: Safety / local tolerability signal APPLIES_BECAUSE: This is explicitly a safety study of a single intra-articular injection. Intra-articular biologics carry risks of local inflammatory reactions (synovitis, flare, pain, swelling, effusion), and any foreign or biologic material can trigger immune or hypersensitivity responses in a small joint. Because the trial's primary purpose is safety, even a moderate rate of treatment-related AEs or a single serious local reaction could halt the program, fail the primary endpoint, or trigger a clinical hold — especially at an early phase where the safety database is thin. LIKELIHOOD: MEDIUM RISK: Trial ...
```

*S6 Prediction (full):*

```
PREDICTION: FAILURE
CONFIDENCE: 0.7
KEY_REASON: Early-phase intra-articular biologic injections for osteoarthritis have a poor track record of demonstrating durable, reproducible benefit in small non-weight-bearing joints like the basal thumb, where high placebo response and thin safety/efficacy databases make a positive, program-advancing result unlikely.
```

**gpt-4o-mini reasoning:**

*S5 Risk Factors (first 200 words):*

```
Here are some key risk factors that could cause the trial NCT02762760 to fail, along with their relevance and likelihood: 1. **RISK: Safety Concerns** - **APPLIES_BECAUSE**: If participants experience significant adverse events or safety signals during the trial, this could halt the study prematurely. Given that this is an early-phase trial, unexpected safety issues might raise red flags for the investigational product. - **LIKELIHOOD**: HIGH 2. **RISK: Efficacy Concerns** - **APPLIES_BECAUSE**: If preliminary efficacy results show that Ampion™ does not significantly improve pain or function compared to placebo, the trial would be deemed unsuccessful. The lack of a strong therapeutic effect would dissuade further development. - **LIKELIHOOD**: MEDIUM 3. **RISK: Enrollment Challenges** - **APPLIES_BECAUSE**: Recruiting sufficient participants with arthritis of the basal thumb joint may be difficult, particularly if the target population is small or if there are challenges in appealing to eligible patients. Delays or difficulties in achieving full enrollment can lead to extended timelines or trial abandonment. - **LIKELIHOOD**: MEDIUM 4. **RISK: Regulatory Hurdles** - **APPLIES_BECAUSE**: Regulatory authorities may raise concerns about the trial design, protocol, or safety data, potentially leading to delays or additional requirements. If the data does not meet regulatory expectations, it could prevent progression ...
```

*S6 Prediction (full):*

```
PREDICTION: FAILURE  
CONFIDENCE: 0.65  
KEY_REASON: The trial is likely to face significant safety concerns and efficacy challenges, which are common in early-phase studies for new treatments in conditions like osteoarthritis.
```

**qwen-plus reasoning:**

*S5 Risk Factors (first 200 words):*

```
RISK: Inadequate safety database for intra-articular use in small joints APPLIES_BECAUSE: Ampion™ had limited prior clinical exposure in the thumb CMC joint — a small, biomechanically complex synovial joint with distinct anatomy and volume constraints; safety signals (e.g., injection-site inflammation, flare, or systemic cytokine effects) observed in earlier knee OA studies may not extrapolate, and small-joint tolerability was uncharacterized. LIKELIHOOD: HIGH RISK: Lack of a concurrent control group APPLIES_BECAUSE: If the trial is single-arm (as suggested by the title’s emphasis on “safety of a single injection” without mention of comparator), it cannot isolate treatment effect from natural history, placebo response, or regression to the mean — rendering efficacy or meaningful safety comparisons impossible. LIKELIHOOD: HIGH RISK: Poor feasibility of enrollment and retention APPLIES_BECAUSE: Basal thumb OA is common but often undertreated; identifying and enrolling patients meeting strict eligibility (e.g., radiographic severity, failure of conservative therapy, willingness to undergo injection) into a single-center or limited-site study targeting a niche indication is historically challenging. LIKELIHOOD: MEDIUM RISK: Insensitive or non-validated outcome measures for thumb-specific function APPLIES_BECAUSE: Generic OA endpoints (e.g., WOMAC, VAS pain) poorly capture basal thumb–specific impairments (e.g., pinch strength, key pinch, tripod stability); absence of validated, joint-specific tools (e.g., QuickDASH ...
```

*S6 Prediction (full):*

```
PREDICTION: FAILURE  
CONFIDENCE: 0.7  
KEY_REASON: The trial’s sole focus on safety without a control group or efficacy endpoints — combined with Ampion™’s unproven mechanism, lack of prior validation in the basal thumb joint, and regulatory challenges surrounding its complex biologic composition — makes it unlikely to generate data sufficient for clinical or regulatory advancement.
```

**Failure signature:** all 3 committed models said FAILURE on a SUCCESS trial; consistent with the shared FAILURE lean; mean S1 recall 0.33; mean stated confidence 0.68

---

### Trial 4: NCT02838823

**Ground truth (`label`):** SUCCESS  
**Phase:** PHASE1  
**Indication:** Breast Cancer  
**Sponsor:** Shanghai Junshi Bioscience Co., Ltd.  
**Drug:** humanized anti-PD-1 monoclonal antibody toripalimab  
**Title:** Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Breast Cancer

| Step | deepseek-chat | gpt-4o-mini | qwen-plus |
|---|---|---|---|
| S1 Trial Recall | 0.00 | 0.00 | 0.00 |
| S2 Reference Class | 0.00 | 1.00 | 0.33 |
| S3 Base Rate | 0.00 | 0.00 | 0.00 |
| S4 Success Criteria | 1.00 | 0.00 | 1.00 |
| S5 Risk Factors | 1.00 | 1.00 | 1.00 |
| S6 Prediction | 0.00 WRONG (FAILURE) | 0.00 WRONG (FAILURE) | 0.00 WRONG (FAILURE) |

**deepseek-chat reasoning:**

*S5 Risk Factors (first 200 words):*

```
I'll answer based on the trial's stated profile (Phase 1, advanced breast cancer, anti-PD-1 monoclonal antibody) and general knowledge of this trial type. These are reasoned risks, not confirmed facts about NCT02838823, whose protocol I have not seen. RISK: Weak single-agent efficacy of anti-PD-1 in breast cancer APPLIES_BECAUSE: Anti-PD-1/PD-L1 monotherapy has historically shown limited activity in breast cancer, particularly in hormone-receptor-positive and HER2-positive disease, and only modest activity in triple-negative breast cancer. If this trial enrolls an unselected advanced breast cancer population, the efficacy signal (if any is measured) is likely to be weak, which could cause the sponsor to abandon development or fail to justify a Phase 2/3. LIKELIHOOD: HIGH RISK: Immune-related adverse events (irAEs) APPLIES_BECAUSE: PD-1 blockade is associated with a well-characterized class of irAEs (colitis, pneumonitis, hepatitis, endocrinopathies, rash). Because the trial's primary endpoint is safety and tolerability, even a modest rate of severe irAEs — especially in a population that may have received prior chemotherapy — could cause DLTs at low dose levels, prevent MTD/RP2D determination, or trigger a clinical hold. LIKELIHOOD: MEDIUM RISK: Enrollment challenges in a crowded immunotherapy landscape APPLIES_BECAUSE: By 2016 (the era of this NCT number), multiple anti-PD-1/PD-L1 agents were already in ...
```

*S6 Prediction (full):*

```
PREDICTION: FAILURE
CONFIDENCE: 0.75
KEY_REASON: Anti-PD-1 monotherapy has historically shown weak and non-durable efficacy in advanced breast cancer, and a small Phase 1 safety/tolerability trial of a largely undifferentiated "me-too" humanized anti-PD-1 antibody is unlikely to generate a signal strong enough to advance development.
```

**gpt-4o-mini reasoning:**

*S5 Risk Factors (first 200 words):*

```
Here are key risk factors that could potentially cause the NCT02838823 trial to fail: 1. **RISK: Efficacy Concerns** - **APPLIES_BECAUSE**: There has been significant development in immunotherapy for breast cancer, but many trials with anti-PD-1/PD-L1 inhibitors have faced challenges in demonstrating consistent efficacy across different subtypes of breast cancer, particularly in advanced cases. If this trial does not show a meaningful response rate or progression-free survival benefit compared to existing treatments, it would be deemed unsuccessful. - **LIKELIHOOD: HIGH** 2. **RISK: Safety Signals from Earlier Phases** - **APPLIES_BECAUSE**: If previous phases indicate adverse safety signals (e.g., unacceptable toxicity rates, severe immune-related side effects), this could raise concerns during enrollment and monitoring in this trial. Safety issues could lead to early termination or a halt in further development. - **LIKELIHOOD: MEDIUM** 3. **RISK: Enrollment Challenges** - **APPLIES_BECAUSE**: Recruiting enough participants who meet the specific eligibility criteria for advanced breast cancer can be difficult. If there are insufficient patients willing or eligible to enter the trial, it could lead to longer timelines or even trial failure if enrollment targets are not met. - **LIKELIHOOD: MEDIUM** 4. **RISK: Competitive Landscape** - **APPLIES_BECAUSE**: The rapid development of other therapies, including other immunotherapies and targeted ...
```

*S6 Prediction (full):*

```
PREDICTION: FAILURE  
CONFIDENCE: 0.65  
KEY_REASON: Despite the potential of anti-PD-1 therapies, historical challenges in demonstrating efficacy for advanced breast cancer, especially in diverse subtypes, have often led to disappointing results in trials.
```

**qwen-plus reasoning:**

*S5 Risk Factors (first 200 words):*

```
RISK: Limited single-agent anti-PD-1 activity in unselected advanced breast cancer APPLIES_BECAUSE: This trial evaluates a recombinant humanized anti-PD-1 monoclonal antibody — a class with well-documented low objective response rates (<5–10%) as monotherapy in unselected metastatic breast cancer, particularly in hormone receptor-positive or HER2-negative subtypes, due to low tumor mutational burden and immunologically “cold” microenvironments. Safety may be acceptable, but failure to identify a signal of biological activity (e.g., stable disease ≥6 months, confirmed responses) could undermine justification for further development. LIKELIHOOD: HIGH RISK: Unacceptable immune-related toxicity in a vulnerable population APPLIES_BECAUSE: Patients with advanced breast cancer are often heavily pretreated, with compromised organ function (e.g., prior anthracyclines → cardiac vulnerability; taxanes → neuropathy), potentially increasing susceptibility to irAEs (e.g., pneumonitis, myocarditis, endocrinopathies). Anti-PD-1 agents carry known risks of severe/fatal irAEs, and early-phase trials lack predictive biomarkers to mitigate exposure in high-risk subgroups. LIKELIHOOD: MEDIUM RISK: Inadequate patient enrollment or high dropout rate APPLIES_BECAUSE: Phase 1 trials in advanced breast cancer face competition from numerous later-phase immunotherapy combination trials and targeted therapy studies; additionally, eligibility criteria (e.g., ECOG PS, organ function, prior immunotherapy) may be restrictive, and patients may decline participation due to perceived low benefit-to-burden ratio in a monotherapy safety ...
```

*S6 Prediction (full):*

```
PREDICTION: FAILURE  
CONFIDENCE: 0.75  
KEY_REASON: Anti-PD-1 monotherapy has consistently demonstrated minimal objective activity in unselected advanced breast cancer across multiple trials, making it highly unlikely this safety-focused Phase 1 trial would yield sufficient evidence of biological effect or tolerability-supported dose selection to justify progression to pivotal development.
```

**Failure signature:** all 3 committed models said FAILURE on a SUCCESS trial; consistent with the shared FAILURE lean; no trial-specific recall (S1=0.00); mean stated confidence 0.72

---

### Trial 5: NCT02855892

**Ground truth (`label`):** SUCCESS  
**Phase:** PHASE2  
**Indication:** Benign Prostatic Hyperplasia (BPH)  
**Sponsor:** GemVax & Kael  
**Drug:** GV1001  
**Title:** A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH

| Step | deepseek-chat | gpt-4o-mini | qwen-plus |
|---|---|---|---|
| S1 Trial Recall | 0.00 | 0.00 | 0.00 |
| S2 Reference Class | 0.00 | 1.00 | 0.00 |
| S3 Base Rate | 0.50 | 1.00 | 0.00 |
| S4 Success Criteria | 0.30 | 0.70 | 0.00 |
| S5 Risk Factors | 0.80 | 0.50 | 0.80 |
| S6 Prediction | 0.00 WRONG (FAILURE) | 0.00 WRONG (FAILURE) | 0.00 WRONG (FAILURE) |

**deepseek-chat reasoning:**

*S5 Risk Factors (first 200 words):*

```
Before listing, an honest caveat: I do not have reliable trial-specific facts about NCT02855892 (its protocol, prior GV1001 safety data in this population, enrollment targets, or endpoints). The risks below are therefore framed around what is *structurally* plausible for a Phase II GV1001 BPH trial, and I mark likelihood as a judgment, not a data-derived figure. RISK: Efficacy failure / weak or unvalidated mechanism in BPH APPLIES_BECAUSE: GV1001 is (to my recollection) a peptide with immunomodulatory/telomerase-associated activity developed mainly in oncology, not a mechanistically validated BPH target. BPH efficacy trials rely on symptom/flow endpoints that are prone to high placebo response and regression to the mean, making it hard for an unproven mechanism to show a clean, clinically meaningful effect. If the drug does not engage a plausible BPH-relevant pathway, the trial can miss its endpoint regardless of execution. LIKELIHOOD: HIGH RISK: Endpoint sensitivity and trial design limitations APPLIES_BECAUSE: Phase II BPH trials often use soft or surrogate endpoints (IPSS change, Qmax) that are subjective, variable, and susceptible to placebo effect. If the trial is underpowered, short in duration, or lacks a robust control/blinding, a real but modest effect can be missed or an apparent effect can fail to replicate. ...
```

*S6 Prediction (full):*

```
PREDICTION: FAILURE
CONFIDENCE: 0.75
KEY_REASON: GV1001 is a peptide with no validated mechanism in BPH, tested in a crowded, placebo-prone indication where soft symptom/flow endpoints make it unlikely to demonstrate a clinically meaningful effect.
```

**gpt-4o-mini reasoning:**

*S5 Risk Factors (first 200 words):*

```
Here are some key risk factors that could potentially cause the clinical trial NCT02855892 to fail, ordered from most to least concerning: 1. **RISK:** Efficacy Concerns - **APPLIES_BECAUSE:** If GV1001 does not demonstrate a statistically significant reduction in BPH symptoms or improvement in quality of life measures compared to control, the trial would likely fail to meet its primary endpoints. Given the existing treatment options for BPH, proving superior efficacy can be particularly challenging. - **LIKELIHOOD:** HIGH 2. **RISK:** Safety Signals - **APPLIES_BECAUSE:** If unexpected adverse events or safety signals arise during the trial, it could lead to halting the study either due to ethical concerns or regulatory scrutiny. Safety is paramount, especially in trials involving new drugs. - **LIKELIHOOD:** MEDIUM 3. **RISK:** Enrollment Challenges - **APPLIES_BECAUSE:** Difficulty in recruiting enough eligible participants can delay or halt the trial. If the trial requires specific inclusion/exclusion criteria that are too strict, or if there is low interest in the study due to existing treatment options, the trial may fail to enroll the required number of patients. - **LIKELIHOOD:** MEDIUM 4. **RISK:** Competitive Landscape - **APPLIES_BECAUSE:** If multiple treatments targeting BPH enter the market or show rapid progression in trials, GV1001 may ...
```

*S6 Prediction (full):*

```
PREDICTION: FAILURE  
CONFIDENCE: 0.65  
KEY_REASON: The presence of significant existing treatments for BPH may make it difficult for GV1001 to demonstrate superior efficacy in a competitive landscape.
```

**qwen-plus reasoning:**

*S5 Risk Factors (first 200 words):*

```
- RISK: Lack of plausible biological mechanism in BPH APPLIES_BECAUSE: GV1001 is a telomerase-derived peptide vaccine developed initially for cancer immunotherapy; there is no established pathophysiological link between telomerase modulation and BPH pathogenesis (which is driven by androgen signaling, stromal proliferation, and inflammation), making clinical efficacy biologically implausible. LIKELIHOOD: HIGH - RISK: Prior clinical failure in oncology indications APPLIES_BECAUSE: GV1001 failed to meet primary endpoints in multiple Phase III cancer trials (e.g., NSCLC, pancreatic cancer), raising concerns about its clinical activity as a therapeutic agent — undermining confidence in repurposing for a non-oncologic, non-immunogenic indication like BPH. LIKELIHOOD: HIGH - RISK: Unknown trial conduct status and lack of published results APPLIES_BECAUSE: NCT02855892 has no posted results on ClinicalTrials.gov as of public knowledge cutoff, and the study was listed as "Completed" with no outcome data — suggesting possible early termination, inability to enroll, or negative findings that precluded reporting. LIKELIHOOD: MEDIUM - RISK: Absence of validated biomarkers or pharmacodynamic measures in BPH APPLIES_BECAUSE: No known surrogate markers exist to confirm target engagement or biological effect of GV1001 in prostate tissue or serum — making it difficult to interpret null clinical outcomes or guide dose/ regimen optimization. LIKELIHOOD: MEDIUM - RISK: Competitive ...
```

*S6 Prediction (full):*

```
PREDICTION: FAILURE  
CONFIDENCE: 0.9  
KEY_REASON: GV1001 lacks a plausible biological mechanism of action in BPH and has already failed in multiple Phase III cancer trials, making clinical efficacy in this unrelated indication highly improbable.
```

**Failure signature:** all 3 committed models said FAILURE on a SUCCESS trial; consistent with the shared FAILURE lean; no trial-specific recall (S1=0.00); mean stated confidence 0.77

---

### Trial 6: NCT02890719

**Ground truth (`label`):** FAILURE  
**Phase:** PHASE3  
**Indication:** Liver Transplantation; Hepatitis C  
**Sponsor:** Fundacion Clinic per a la Recerca Biomédica  
**Drug:** Grazoprevir 100 mg/day  
**Title:** Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients.

| Step | deepseek-chat | gpt-4o-mini | qwen-plus |
|---|---|---|---|
| S1 Trial Recall | 0.00 | 0.00 | 0.00 |
| S2 Reference Class | 0.00 | 1.00 | 0.33 |
| S3 Base Rate | 0.00 | 0.50 | 0.00 |
| S4 Success Criteria | 1.00 | 1.00 | 1.00 |
| S5 Risk Factors | 0.80 | 0.50 | 0.80 |
| S6 Prediction | 0.00 WRONG (SUCCESS) | 0.00 WRONG (SUCCESS) | 0.00 WRONG (SUCCESS) |

**deepseek-chat reasoning:**

*S5 Risk Factors (first 200 words):*

```
RISK: Drug–drug interactions between grazoprevir/elbasvir and immunosuppressants APPLIES_BECAUSE: Liver transplant recipients are maintained on calcineurin inhibitors (tacrolimus, cyclosporine) and other immunosuppressants. Grazoprevir and elbasvir are CYP3A and OATP1B substrates/inhibitors, and cyclosporine in particular is known to substantially raise grazoprevir exposure, raising concerns for hepatotoxicity and requiring dose caps or avoidance. This is the central safety issue specific to this population and could produce toxicity signals, dose-limiting events, or treatment discontinuation. LIKELIHOOD: HIGH RISK: Enrollment challenges in a narrow, medically complex population APPLIES_BECAUSE: The eligible pool is limited to liver transplant recipients with chronic HCV who are stable enough to start DAA therapy, on stable immunosuppression, and willing to be randomized to 12 vs 16 weeks. Many such patients may be treated off-protocol with approved DAAs rather than enrolled, and an investigator-initiated pilot typically has a small target sample. Slow or incomplete enrollment can lead to premature termination or underpowered results. LIKELIHOOD: HIGH RISK: Competing approved therapies making the trial question obsolete APPLIES_BECAUSE: By the time this trial was conducted, multiple pan-genotypic DAA regimens were approved for HCV, and transplant-recipient treatment was increasingly standard of care. Clinicians and patients may prefer an approved regimen with established transplant data over an experimental ...
```

*S6 Prediction (full):*

```
PREDICTION: SUCCESS
CONFIDENCE: 0.6
KEY_REASON: Direct-acting antiviral combinations like grazoprevir/elbasvir achieve very high SVR rates in HCV, and transplant recipients have generally responded well in similar DAA trials, so the main uncertainty is the safety/tolerability interaction with immunosuppressants rather than efficacy — but I have not verified this specific trial's actual results, so my confidence is moderate rather than high.
```

**gpt-4o-mini reasoning:**

*S5 Risk Factors (first 200 words):*

```
1. **RISK:** Efficacy Concerns **APPLIES_BECAUSE:** Although Grazoprevir and Elbasvir have shown effectiveness in patients with hepatitis C, the specific subpopulation of liver transplant recipients may have unique responses or complications that were not captured in previous trials. If the trial fails to demonstrate a meaningful SVR rate compared to the control, it could be deemed unsuccessful. **LIKELIHOOD:** MEDIUM 2. **RISK:** Safety Signals **APPLIES_BECAUSE:** If safety concerns arise during the trial, such as adverse effects that are more severe or frequent in the liver transplant recipient population compared to prior studies, this could halt the trial or lead to modifications in the treatment regimen. Immunosuppressed patients often have different safety profiles, which could lead to unexpected complications. **LIKELIHOOD:** MEDIUM 3. **RISK:** Enrollment Challenges **APPLIES_BECAUSE:** Recruiting a sufficient number of liver transplant recipients who are eligible for the trial can be challenging due to strict inclusion and exclusion criteria as well as a potentially limited patient population. Insufficient enrollment could delay the trial or prevent it from achieving statistical power. **LIKELIHOOD:** HIGH 4. **RISK:** Regulatory Issues **APPLIES_BECAUSE:** If there are any unexpected regulatory hurdles or if the trial design does not meet the expectations of regulatory agencies, this could result in delays ...
```

*S6 Prediction (full):*

```
PREDICTION: SUCCESS  
CONFIDENCE: 0.75  
KEY_REASON: The combination of Grazoprevir and Elbasvir has a strong efficacy profile in treating hepatitis C, and given the advancements in direct-acting antiviral therapies, it is likely to demonstrate meaningful results in liver transplant recipients.
```

**qwen-plus reasoning:**

*S5 Risk Factors (first 200 words):*

```
RISK: Insufficient enrollment / premature termination due to recruitment challenges APPLIES_BECAUSE: Liver transplant recipients with chronic HCV represent a small, geographically dispersed, and medically complex population; pilot trials in this group frequently struggle with slow accrual, protocol exclusions (e.g., renal impairment, drug interactions, decompensation), and competing standard-of-care options post-2015. LIKELIHOOD: HIGH RISK: Drug–immunosuppressant interactions leading to safety events or dosing disruptions APPLIES_BECAUSE: Grazoprevir (a CYP3A4 substrate/inhibitor) and elbasvir (a P-gp and BCRP substrate) have known pharmacokinetic interactions with calcineurin inhibitors (tacrolimus, cyclosporine) and mTOR inhibitors (sirolimus) — mainstays of post-transplant immunosuppression. Unanticipated toxicity (e.g., nephrotoxicity, neurotoxicity, graft dysfunction) could halt dosing or lead to discontinuation. LIKELIHOOD: HIGH RISK: Suboptimal efficacy (low SVR12) due to baseline resistance-associated substitutions (RASs) APPLIES_BECAUSE: Elbasvir is highly susceptible to NS5A RASs (e.g., Y93H, L31M/V), which are more prevalent in prior treatment-experienced and post-transplant HCV patients; grazoprevir also has reduced activity against certain NS3 RASs. The trial did not specify RAS screening — a known design limitation for this regimen in high-risk populations. LIKELIHOOD: MEDIUM RISK: Lack of a control arm or comparative benchmark, limiting interpretability of efficacy APPLIES_BECAUSE: As a pilot study comparing only two durations (12 vs. 16 weeks) without concurrent controls (e.g., historical ...
```

*S6 Prediction (full):*

```
PREDICTION: SUCCESS  
CONFIDENCE: unknown  
KEY_REASON: I cannot determine the actual outcome of NCT02890719 or reliably assess success without access to its results — and no outcome data is within my knowledge base.
```

**Failure signature:** all 3 committed models said SUCCESS on a FAILURE trial; no trial-specific recall (S1=0.00); mean stated confidence 0.68

---

### Trial 7: NCT02906579

**Ground truth (`label`):** SUCCESS  
**Phase:** PHASE2  
**Indication:** Diabetes Mellitus, Type 2; Hypertension  
**Sponsor:** Cyclerion Therapeutics  
**Drug:** Matching Placebo  
**Title:** A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension

| Step | deepseek-chat | gpt-4o-mini | qwen-plus |
|---|---|---|---|
| S1 Trial Recall | 0.00 | 0.00 | 0.00 |
| S2 Reference Class | 0.00 | 1.00 | 0.33 |
| S3 Base Rate | 1.00 | 1.00 | 0.50 |
| S4 Success Criteria | 0.30 | 0.00 | 0.00 |
| S5 Risk Factors | 0.50 | 0.50 | 0.80 |
| S6 Prediction | 0.00 WRONG (FAILURE) | 0.00 WRONG (FAILURE) | 0.00 WRONG (FAILURE) |

**deepseek-chat reasoning:**

*S5 Risk Factors (first 200 words):*

```
I'll reason from the title, indication, drug class, and general Phase 2 experience. All specifics about NCT02906579's protocol are unknown to me, so these are inferred risks, not confirmed facts. --- **RISK 1: Mechanism does not translate to a measurable benefit in a diabetic/hypertensive population** - **APPLIES_BECAUSE:** sGC stimulators act on the NO–sGC–cGMP pathway to produce vasodilation, but the class's track record in diabetes-adjacent and cardiometabolic indications is equivocal — riociguat's diabetic nephropathy program reportedly missed its primary endpoint, and vericiguat failed in HFpEF before succeeding in HFrEF. In type 2 diabetes with hypertension, background standard-of-care (ACE inhibitors/ARBs, metformin, etc.) already addresses the same pathways, so the incremental effect of an sGC stimulator over optimized background therapy may be small. A Phase 2 with intermediate endpoints (BP, HbA1c, albuminuria) may simply not show separation from control. - **LIKELIHOOD:** HIGH --- **RISK 2: Safety/tolerability signals — hypotension and hemodynamic effects** - **APPLIES_BECAUSE:** Vasodilators that act on the cGMP pathway predictably lower blood pressure, and the target population is already hypertensive and frequently on multiple antihypertensive agents, raising the risk of symptomatic hypotension, dizziness, syncope, or falls. sGC stimulators have also been associated with anemia and gastrointestinal effects in some programs. In ...
```

*S6 Prediction (full):*

```
PREDICTION: FAILURE
CONFIDENCE: 0.72
KEY_REASON: sGC stimulators have a weak track record in diabetes-adjacent cardiometabolic indications (e.g., riociguat's diabetic nephropathy program reportedly missed its endpoint), and in a Phase 2 population already on optimized standard-of-care for hypertension and type 2 diabetes, the incremental BP/glycemic effect is likely too small to reach statistical significance.
```

**gpt-4o-mini reasoning:**

*S5 Risk Factors (first 200 words):*

```
1. **RISK: Efficacy Concerns** **APPLIES_BECAUSE:** If preliminary data or past Phase 1 trials did not show significant efficacy of IW-1973 in lowering blood pressure or improving glycemic control in patients with Type 2 Diabetes and Hypertension, it raises doubts about its effectiveness in Phase 2. There could also be a lack of robust data from similar compounds that suggest limited benefits in this patient population. **LIKELIHOOD:** HIGH 2. **RISK: Safety Signals** **APPLIES_BECAUSE:** If there are any adverse effects or safety signals reported in previous trials involving IW-1973 or related sGC stimulators, this could lead to heightened scrutiny from regulators or a halt to the trial due to concerns about patient safety. **LIKELIHOOD:** MEDIUM 3. **RISK: Enrollment Challenges** **APPLIES_BECAUSE:** Given the specific patient population (stable Type 2 Diabetes and Hypertension), there may be challenges in recruiting enough eligible and willing participants to meet enrollment targets, particularly if there are stringent inclusion/exclusion criteria, or if competing trials are ongoing. **LIKELIHOOD:** MEDIUM 4. **RISK: Competitive Landscape** **APPLIES_BECAUSE:** The existence of numerous established treatments for Type 2 Diabetes and Hypertension, as well as emerging therapies, could result in a crowded market, making it difficult for IW-1973 to prove its unique benefit and gain traction, ...
```

*S6 Prediction (full):*

```
PREDICTION: FAILURE  
CONFIDENCE: 0.65  
KEY_REASON: The competitive landscape and potential efficacy concerns with soluble guanylate cyclase stimulators may hinder IW-1973's ability to demonstrate a significant clinical benefit in the target population.
```

**qwen-plus reasoning:**

*S5 Risk Factors (first 200 words):*

```
- RISK: Insufficient efficacy signal on blood pressure or glycemic endpoints APPLIES_BECAUSE: sGC stimulators primarily act via the NO-sGC-cGMP pathway to promote vasodilation — their effects on insulin sensitivity or glucose metabolism are indirect and mechanistically unproven in humans; dual improvement in both hypertension and type 2 diabetes is biologically ambitious and unsupported by prior clinical data for this class. LIKELIHOOD: HIGH - RISK: Safety/tolerability issues (e.g., hypotension, syncope, anemia) APPLIES_BECAUSE: sGC stimulators are known to cause dose-dependent blood pressure lowering and reflex tachycardia; patients with type 2 diabetes often have autonomic dysfunction and baseline orthostatic vulnerability, increasing risk of symptomatic hypotension — a well-documented class effect observed with riociguat and vericiguat in other populations. LIKELIHOOD: HIGH - RISK: Inadequate patient enrollment or high dropout rate APPLIES_BECAUSE: The trial targets *stable* type 2 diabetes *and* hypertension — a population typically on multiple antihypertensives and glucose-lowering agents, making eligibility stringent (e.g., exclusion for recent CV events, renal impairment, or lab abnormalities); polypharmacy and comorbidities commonly lead to screening failures and attrition in Phase 2 metabolic trials. LIKELIHOOD: MEDIUM - RISK: Pharmacodynamic–pharmacokinetic disconnect in target population APPLIES_BECAUSE: Patients with diabetes and hypertension frequently exhibit oxidative stress and sGC oxidation/desensitization — which impairs ...
```

*S6 Prediction (full):*

```
PREDICTION: FAILURE  
CONFIDENCE: 0.85  
KEY_REASON: sGC stimulators have no established mechanistic rationale or clinical evidence for meaningful dual efficacy in both type 2 diabetes and hypertension, and the high likelihood of hypotension-related safety issues in this vulnerable population makes successful risk–benefit demonstration improbable.
```

**Failure signature:** all 3 committed models said FAILURE on a SUCCESS trial; consistent with the shared FAILURE lean; no trial-specific recall (S1=0.00); mean stated confidence 0.74

---

### Trial 8: NCT03033524

**Ground truth (`label`):** SUCCESS  
**Phase:** PHASE2  
**Indication:** Recurrent Glioblastoma  
**Sponsor:** PharmAbcine  
**Drug:** TTAC-0001  
**Title:** Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent Glioblastoma

| Step | deepseek-chat | gpt-4o-mini | qwen-plus |
|---|---|---|---|
| S1 Trial Recall | 1.00 | 0.00 | 0.00 |
| S2 Reference Class | 1.00 | 1.00 | 0.00 |
| S3 Base Rate | 0.50 | 0.50 | 0.00 |
| S4 Success Criteria | 1.00 | 0.00 | 1.00 |
| S5 Risk Factors | 0.75 | 1.00 | 1.00 |
| S6 Prediction | 0.00 WRONG (FAILURE) | 0.00 WRONG (FAILURE) | 0.00 WRONG (FAILURE) |

**deepseek-chat reasoning:**

*S5 Risk Factors (first 200 words):*

```
RISK: Lack of efficacy of anti-VEGFR-2 monotherapy in recurrent glioblastoma APPLIES_BECAUSE: The drug is tanibirumab, an anti-VEGFR-2 antibody, and recurrent GBM is notoriously resistant to anti-angiogenic monotherapy. Comparable agents in this class (cediranib, aflibercept, sunitinib, sorafenib) largely failed to improve overall survival in recurrent GBM, and even bevacizumab — the most successful anti-angiogenic in this setting — did not confirm an OS benefit in randomized trials. This is the single most likely reason a safety-focused Phase 2 would not translate into further development. LIKELIHOOD: HIGH RISK: Blood-brain barrier / tumor penetration limiting target engagement APPLIES_BECAUSE: Tanibirumab is a large monoclonal antibody, and antibody penetration into glioblastoma tissue (especially beyond the enhancing rim) is generally poor. Even with a valid mechanism, the drug may not reach its target in sufficient concentration in the brain tumor microenvironment, undermining any efficacy signal regardless of systemic activity. LIKELIHOOD: HIGH RISK: Safety/tolerability signals (hemorrhage, hypertension, thromboembolism, wound-healing) APPLIES_BECAUSE: Anti-VEGF/VEGFR agents carry well-known class toxicities, including intracranial hemorrhage — a particular concern in glioblastoma, where tumors are vascular and often previously irradiated. Because the trial's stated purpose is to evaluate safety, any excess of these events (especially CNS hemorrhage) could halt the trial or block further ...
```

*S6 Prediction (full):*

```
PREDICTION: FAILURE
CONFIDENCE: 0.9
KEY_REASON: Anti-VEGFR-2 antibody therapy in recurrent glioblastoma faces poor brain penetration and a near-uniform historical record of anti-angiogenic agents failing to improve overall survival in this indication, making a positive efficacy outcome highly unlikely.
```

**gpt-4o-mini reasoning:**

*S5 Risk Factors (first 200 words):*

```
Here are some key risk factors that could potentially cause the trial (NCT03033524) to fail, ordered from most to least concerning: 1. **RISK: Efficacy Concerns** **APPLIES_BECAUSE**: Given that glioblastoma is a notoriously aggressive and treatment-resistant cancer, there is a significant risk that TTAC-0001 may not demonstrate meaningful efficacy in improving overall survival or progression-free survival compared to existing treatments. Previous trials in this indication may suggest a low likelihood of success, making this a critical concern for the trial. **LIKELIHOOD: HIGH** 2. **RISK: Safety Signals from Earlier Phases** **APPLIES_BECAUSE**: If previous studies of TTAC-0001 have identified safety signals or adverse effects that are concerning, these could hinder enrollment and lead to heightened scrutiny from regulatory bodies, ultimately jeopardizing the trial. Safety is paramount, especially in trials involving a vulnerable population like those with recurrent glioblastoma. **LIKELIHOOD: MEDIUM** 3. **RISK: Enrollment Challenges** **APPLIES_BECAUSE**: Recruiting enough eligible patients for a trial in recurrent glioblastoma can be difficult, especially given the limited number of patients who meet inclusion criteria and the competitive landscape of ongoing trials in this space. Enrollment is crucial for meeting statistical power and achieving meaningful results. **LIKELIHOOD: MEDIUM** 4. **RISK: Regulatory Issues** **APPLIES_BECAUSE**: Regulatory bodies may impose additional requirements ...
```

*S6 Prediction (full):*

```
PREDICTION: FAILURE  
CONFIDENCE: 0.70  
KEY_REASON: The aggressive nature of recurrent glioblastoma and the historical low success rate of clinical trials in this indication lead to a high likelihood of the trial not demonstrating meaningful efficacy.
```

**qwen-plus reasoning:**

*S5 Risk Factors (first 200 words):*

```
- RISK: Insufficient single-agent antitumor activity in recurrent glioblastoma APPLIES_BECAUSE: Recurrent GBM is characterized by profound therapeutic resistance, poor drug penetration across the blood–brain barrier, and immunosuppressive tumor microenvironment — all of which severely limit efficacy of systemic agents, especially monotherapies; TTAC-0001 (Tanibirumab) is a monoclonal antibody (based on naming convention), and no prior clinical data is accessible to confirm target engagement or biological activity in CNS tumors. LIKELIHOOD: HIGH - RISK: Poor tolerability or unexpected neurotoxicity APPLIES_BECAUSE: The trial’s primary objective is safety evaluation, implying uncertainty about the agent’s toxicity profile — particularly concerning for antibodies targeting CNS-expressed antigens (e.g., potential for neuroinflammation, edema, or immune-related adverse events in brain tissue); glioblastoma patients often have compromised neurological status and are highly sensitive to treatment-related deterioration. LIKELIHOOD: HIGH - RISK: Inadequate patient enrollment or high dropout rate APPLIES_BECAUSE: Recurrent GBM has a short median survival (~6–9 months), rapid clinical decline, and stringent eligibility criteria (e.g., performance status, prior therapies, imaging requirements); safety-focused early-phase trials in this population frequently struggle with slow accrual and early discontinuation due to progression or toxicity. LIKELIHOOD: MEDIUM - RISK: Lack of validated pharmacodynamic or biomarker signal APPLIES_BECAUSE: Without evidence of target modulation (e.g., receptor occupancy, ...
```

*S6 Prediction (full):*

```
PREDICTION: FAILURE  
CONFIDENCE: 0.85  
KEY_REASON: Safety-focused Phase 2 trials in recurrent glioblastoma with novel monoclonal antibodies historically fail to demonstrate sufficient single-agent activity or tolerability to support further development, and the absence of efficacy endpoints or a control arm in this trial design precludes meaningful demonstration of clinical benefit.
```

**Failure signature:** all 3 committed models said FAILURE on a SUCCESS trial; consistent with the shared FAILURE lean; mean S1 recall 0.33; mean stated confidence 0.82

---

### Trial 9: NCT03101579

**Ground truth (`label`):** SUCCESS  
**Phase:** PHASE1  
**Indication:** Leptomeningeal Metastases  
**Sponsor:** The First Hospital of Jilin University  
**Drug:** Pemetrexed  
**Title:** Intrathecal Pemetrexed for Recurrent Leptomeningeal Metastases From Non-small Cell Lung Cancer

| Step | deepseek-chat | gpt-4o-mini | qwen-plus |
|---|---|---|---|
| S1 Trial Recall | 0.00 | 0.00 | 0.00 |
| S2 Reference Class | 0.00 | 1.00 | 0.33 |
| S3 Base Rate | 0.00 | 0.00 | 0.00 |
| S4 Success Criteria | 0.70 | 0.00 | 0.00 |
| S5 Risk Factors | 1.00 | 1.00 | 1.00 |
| S6 Prediction | 0.00 WRONG (FAILURE) | 0.00 WRONG (FAILURE) | 0.00 WRONG (FAILURE) |

**deepseek-chat reasoning:**

*S5 Risk Factors (first 200 words):*

```
RISK: Intrathecal neurotoxicity / safety signal from direct CNS drug delivery APPLIES_BECAUSE: Pemetrexed is normally given intravenously; delivering it directly into the CSF exposes the brain and spinal cord to high local concentrations of an antifolate, which carries risk of chemical meningitis, arachnoiditis, myelopathy, seizures, or encephalopathy. In a phase 1 context, a single severe neurotoxicity event could halt dose escalation or the whole trial. Leptomeningeal disease patients are also neurologically fragile, making toxicity hard to distinguish from disease progression. LIKELIHOOD: HIGH RISK: Efficacy failure / weak response signal in a hard-to-treat compartment APPLIES_BECAUSE: Leptomeningeal metastases are notoriously chemoresistant, and prior intrathecal and systemic therapies have shown modest response rates. Pemetrexed's ability to control leptomeningeal disease when given intrathecally was unproven before this trial, and the patient population is heavily pretreated (recurrent LM). If CSF cytology clearance or survival benefit falls below the pre-specified threshold, the trial fails its efficacy bar. LIKELIHOOD: HIGH RISK: Trial design limitations (single-arm, small sample, no control) APPLIES_BECAUSE: Early-phase LM trials are typically small, single-arm, and open-label, with historical or no controls. This limits statistical power and makes any efficacy signal difficult to attribute to the drug versus natural history, supportive care, or selection bias. ...
```

*S6 Prediction (full):*

```
PREDICTION: FAILURE
CONFIDENCE: 0.6
KEY_REASON: Intrathecal pemetrexed faces a high bar in a chemoresistant, fragile leptomeningeal metastasis population where safety and efficacy signals are difficult to demonstrate, and early-phase LM trials rarely achieve definitive success.
```

**gpt-4o-mini reasoning:**

*S5 Risk Factors (first 200 words):*

```
Here are some key risk factors that could potentially cause NCT03101579 to fail, ordered from most to least concerning: 1. **RISK: Efficacy Concerns** - **APPLIES_BECAUSE**: Leptomeningeal metastases typically present a challenging prognosis, and prior treatments have often shown limited success. If intrathecal pemetrexed does not demonstrate significant efficacy in improving survival or other clinical outcomes compared to historical benchmarks, the trial could be deemed a failure. - **LIKELIHOOD: HIGH** 2. **RISK: Safety Signals from Earlier Phases** - **APPLIES_BECAUSE**: If there are significant safety issues or adverse events reported from earlier studies involving intrathecal pemetrexed or related agents, it may lead to concerns about the risk-benefit profile. This could result in study modifications, halting of the trial, or negative perceptions from regulatory bodies. - **LIKELIHOOD: MEDIUM** 3. **RISK: Enrollment Challenges** - **APPLIES_BECAUSE**: Recruiting patients with recurrent leptomeningeal metastases can be particularly challenging due to the nature of the disease and the urgency of treatment required. If enrollment is slower than projected, it could delay the trial and potentially lead to insufficient data to assess outcomes adequately. - **LIKELIHOOD: MEDIUM** 4. **RISK: Regulatory Issues** - **APPLIES_BECAUSE**: If the trial does not meet regulatory standards or faces scrutiny during the review process, this ...
```

*S6 Prediction (full):*

```
PREDICTION: FAILURE  
CONFIDENCE: 0.75  
KEY_REASON: The historically poor prognosis and limited efficacy of treatments for leptomeningeal metastases make it likely that intrathecal pemetrexed will struggle to demonstrate significant improvement compared to existing therapeutic options.
```

**qwen-plus reasoning:**

*S5 Risk Factors (first 200 words):*

```
RISK: Neurotoxicity or severe CSF-related adverse events (e.g., chemical meningitis, arachnoiditis, myelopathy) APPLIES_BECAUSE: Intrathecal administration of cytotoxic chemotherapy carries well-documented risks of neuroinflammation and neural injury; pemetrexed is not formulated or approved for intrathecal use, and its safety profile in the CSF compartment is entirely unknown — making unexpected, dose-limiting neurotoxicity the most plausible reason for early termination in a Phase 1 trial. LIKELIHOOD: HIGH RISK: Inadequate drug exposure or pharmacokinetic failure in CSF APPLIES_BECAUSE: Pemetrexed is highly protein-bound and hydrophilic, with poor passive diffusion across the blood–CSF barrier; even with direct intrathecal injection, its distribution within the leptomeningeal space may be heterogeneous and short-lived, potentially failing to achieve therapeutic concentrations at tumor sites — undermining any chance of efficacy signal detection. LIKELIHOOD: HIGH RISK: Poor patient accrual or high dropout rate APPLIES_BECAUSE: Leptomeningeal metastases from NSCLC is a rare, rapidly progressive condition with median survival often <3 months off therapy; eligible patients frequently present with significant neurologic impairment (e.g., gait disturbance, cranial nerve deficits), limiting ability to consent, travel, or tolerate repeated lumbar punctures — all critical for an intrathecal dosing trial. LIKELIHOOD: MEDIUM RISK: Lack of objective, reproducible efficacy signal in exploratory endpoints APPLIES_BECAUSE: Phase 1 trials like ...
```

*S6 Prediction (full):*

```
PREDICTION: FAILURE  
CONFIDENCE: 0.85  
KEY_REASON: Intrathecal pemetrexed lacks a biologically plausible pharmacokinetic profile for sustained therapeutic exposure in the CSF, and no clinical evidence supports its activity against leptomeningeal disease — making efficacy failure highly probable despite acceptable safety.
```

**Failure signature:** all 3 committed models said FAILURE on a SUCCESS trial; consistent with the shared FAILURE lean; no trial-specific recall (S1=0.00); mean stated confidence 0.73

---

## Also scored 0.0 everywhere, but involving an abstention

| NCT | truth | phase | deepseek-chat | gpt-4o-mini | qwen-plus |
|---|---|---|---|---|---|
| NCT02456714 | SUCCESS | PHASE2 | WRONG (FAILURE) | WRONG (FAILURE) | ABSTAINED |
| NCT02715193 | SUCCESS | PHASE1 | WRONG (FAILURE) | WRONG (FAILURE) | ABSTAINED |
| NCT02724878 | SUCCESS | PHASE2 | WRONG (FAILURE) | WRONG (FAILURE) | ABSTAINED |
| NCT02735863 | SUCCESS | PHASE2 | WRONG (FAILURE) | WRONG (FAILURE) | ABSTAINED |
| NCT02820896 | SUCCESS | PHASE1 | WRONG (FAILURE) | WRONG (FAILURE) | ABSTAINED |
| NCT02831660 | FAILURE | PHASE3 | WRONG (SUCCESS) | WRONG (SUCCESS) | ABSTAINED |
| NCT02947048 | SUCCESS | PHASE2 | WRONG (FAILURE) | WRONG (FAILURE) | ABSTAINED |
| NCT02967731 | SUCCESS | PHASE1 | WRONG (FAILURE) | ABSTAINED | ABSTAINED |
| NCT03027661 | SUCCESS | PHASE3 | WRONG (FAILURE) | WRONG (FAILURE) | ABSTAINED |
| NCT03047096 | SUCCESS | PHASE1 | WRONG (FAILURE) | WRONG (FAILURE) | ABSTAINED |
| NCT03120832 | SUCCESS | PHASE1 | WRONG (FAILURE) | WRONG (FAILURE) | ABSTAINED |
| NCT03272009 | SUCCESS | PHASE1 | WRONG (FAILURE) | ABSTAINED | ABSTAINED |
| NCT03298464 | SUCCESS | PHASE1 | WRONG (FAILURE) | WRONG (FAILURE) | ABSTAINED |
| NCT03334214 | SUCCESS | PHASE2 | WRONG (FAILURE) | WRONG (FAILURE) | ABSTAINED |
| NCT03679624 | FAILURE | PHASE2 | WRONG (SUCCESS) | WRONG (SUCCESS) | ABSTAINED |
| NCT04247594 | FAILURE | PHASE2 | WRONG (SUCCESS) | WRONG (SUCCESS) | ABSTAINED |
| NCT04274452 | FAILURE | PHASE3 | WRONG (SUCCESS) | WRONG (SUCCESS) | ABSTAINED |

## Comparison: 3 Correctly-Predicted Trials

Sampled with a fixed seed from the 34 trials every model got right.


### Baseline 1: NCT02743546

**Ground truth (`label`):** FAILURE  
**Phase:** PHASE1  
**Indication:** Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell  
**Sponsor:** Janssen Research & Development, LLC  
**Drug:** Duvortuxizumab  
**Title:** Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma

| Step | deepseek-chat | gpt-4o-mini | qwen-plus |
|---|---|---|---|
| S1 Trial Recall | 1.00 | 0.00 | 1.00 |
| S2 Reference Class | 0.00 | 1.00 | 0.33 |
| S3 Base Rate | 0.00 | 0.00 | 0.00 |
| S4 Success Criteria | 0.70 | 0.30 | 0.70 |
| S5 Risk Factors | 0.80 | 0.50 | 0.80 |
| S6 Prediction | 1.00 CORRECT | 1.00 CORRECT | 1.00 CORRECT |

**deepseek-chat reasoning:**

*S6 Prediction (full):*

```
PREDICTION: FAILURE
CONFIDENCE: 0.85
KEY_REASON: This is a Phase 1 CD19xCD3 bispecific combination whose development I recall being discontinued, with the class's CRS/neurotoxicity risk and a crowded, competitive B-cell lymphoma landscape making a positive, practice-changing result unlikely.
```

**gpt-4o-mini reasoning:**

*S6 Prediction (full):*

```
PREDICTION: FAILURE  
CONFIDENCE: 0.65  
KEY_REASON: The complexities of combination therapies in lymphoma and the high standard for efficacy and safety outcomes make it challenging to achieve a successful result, especially in a competitive landscape with evolving treatment options.
```

**qwen-plus reasoning:**

*S6 Prediction (full):*

```
PREDICTION: FAILURE  
CONFIDENCE: 0.85  
KEY_REASON: Duvortuxizumab (JNJ-64052781) was discontinued from clinical development after NCT02743546, with no subsequent phase 3 trial initiated and no regulatory submissions reported — a definitive indicator of failure to demonstrate sufficient benefit-risk balance to advance.
```

---

### Baseline 2: NCT03170115

**Ground truth (`label`):** FAILURE  
**Phase:** PHASE2  
**Indication:** Rectal Cancer, Adenocarcinoma; Locally Advanced Malignant Neoplasm; Chemoradiation  
**Sponsor:** Instituto Nacional de Cancer, Brazil  
**Drug:** Aspirin  
**Title:** Induction Chemotherapy Plus Chemoradiotherapy With or Without Aspirin in High Risk Rectal Cancer

| Step | deepseek-chat | gpt-4o-mini | qwen-plus |
|---|---|---|---|
| S1 Trial Recall | 0.00 | 0.00 | 0.00 |
| S2 Reference Class | 0.00 | 1.00 | 0.33 |
| S3 Base Rate | 1.00 | 0.50 | 0.00 |
| S4 Success Criteria | 1.00 | 1.00 | 0.30 |
| S5 Risk Factors | 0.80 | 0.80 | 0.80 |
| S6 Prediction | 1.00 CORRECT | 1.00 CORRECT | 1.00 CORRECT |

**deepseek-chat reasoning:**

*S6 Prediction (full):*

```
PREDICTION: FAILURE
CONFIDENCE: 0.65
KEY_REASON: Aspirin is a low-cost repurposed agent with at best a modest incremental effect on top of an already-intensive induction chemotherapy plus chemoradiotherapy backbone, making a statistically detectable efficacy win in a phase 2 high-risk rectal cancer trial unlikely.
```

**gpt-4o-mini reasoning:**

*S6 Prediction (full):*

```
PREDICTION: FAILURE  
CONFIDENCE: 0.6  
KEY_REASON: The combination of induction chemotherapy and chemoradiotherapy with aspirin may not provide a significant enough benefit over standard treatment to justify its use, stemming from concerns about efficacy based on previous trials in this domain.
```

**qwen-plus reasoning:**

*S6 Prediction (full):*

```
PREDICTION: FAILURE  
CONFIDENCE: unknown  
KEY_REASON: I cannot reliably predict the outcome without access to the trial’s design details, results, or published findings — and per instructions, I must not fabricate or infer unverifiable information.
```

---

### Baseline 3: NCT04579666

**Ground truth (`label`):** FAILURE  
**Phase:** PHASE2  
**Indication:** Amyotrophic Lateral Sclerosis; Motor Neuron Disease  
**Sponsor:** Apellis Pharmaceuticals, Inc.  
**Drug:** Pegcetacoplan (APL-2)  
**Title:** MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)

| Step | deepseek-chat | gpt-4o-mini | qwen-plus |
|---|---|---|---|
| S1 Trial Recall | 1.00 | 0.00 | 1.00 |
| S2 Reference Class | 1.00 | 1.00 | 0.33 |
| S3 Base Rate | 0.00 | 1.00 | 0.00 |
| S4 Success Criteria | 0.70 | 0.30 | 0.00 |
| S5 Risk Factors | 0.55 | 0.50 | 0.80 |
| S6 Prediction | 1.00 CORRECT | 1.00 CORRECT | 1.00 CORRECT |

**deepseek-chat reasoning:**

*S6 Prediction (full):*

```
PREDICTION: FAILURE
CONFIDENCE: 0.9
KEY_REASON: ALS has an exceptionally poor track record of translating mechanism-based Phase 2 signals into clinical benefit, and complement inhibition in particular has not demonstrated disease-modifying success in this indication, making a positive efficacy readout unlikely.
```

**gpt-4o-mini reasoning:**

*S6 Prediction (full):*

```
PREDICTION: FAILURE  
CONFIDENCE: 0.65  
KEY_REASON: The complexities of ALS and the historically low success rates for Phase 2 trials in this indication raise significant concerns about both efficacy and safety outcomes for pegcetacoplan.
```

**qwen-plus reasoning:**

*S6 Prediction (full):*

```
PREDICTION: FAILURE  
CONFIDENCE: 0.72  
KEY_REASON: The trial tests a biologically plausible but unvalidated mechanism (systemic C3 inhibition) in ALS — a disease where no novel neuroprotective or anti-inflammatory agent has demonstrated robust, reproducible clinical benefit in Phase 3, and where pegcetacoplan lacks evidence of target engagement or efficacy signal in the CNS compartment most relevant to motor neuron degeneration.
```

---

## Are the models predicting outcome, or just phase?

The dataset is balanced 50/50 **within every phase**, so "phase 3 trials tend to succeed" carries no information here: a predictor that follows it scores 0.500, i.e. chance. Yet the predicted-SUCCESS rate swings hard by phase.

```
phase      true SUCCESS  deepseek-cha   gpt-4o-mini     qwen-plus
-----------------------------------------------------------------
PHASE1              50%           24%           12%           39%   (n=34)
PHASE2              50%           26%           29%           18%   (n=34)
PHASE3              50%           72%           84%           59%   (n=32)
```

| model | r(pred, is-phase-3) | r(pred, TRUE label) |
|---|---|---|
| deepseek-chat | +0.443 | +0.362 |
| gpt-4o-mini | +0.600 | +0.162 |
| qwen-plus | +0.303 | +0.611 |

**deepseek-chat, gpt-4o-mini** correlate more strongly with the trial's phase than with its actual outcome — their S6 answer is closer to a phase lookup than to a judgement about the trial. That is also why the intermediate steps fail to predict S6 in the cross-model report: the answer is largely fixed by the phase prior before any trial-specific reasoning happens.

**qwen-plus** track the true label more than the phase. For a model that also abstains heavily, this is the expected shape: it declines instead of falling back on the phase prior, which is why its accuracy-when-answered is the highest of the three.

## Cross-Trial Patterns

- **Direction.** 6/9 of the shared-false-belief trials are SUCCESS trials. Counting abstentions too, 19/26 are SUCCESS. The models fail asymmetrically: they miss successes far more than they miss failures.
- **Phase.** Shared false belief: {'PHASE1': 3, 'PHASE2': 3, 'PHASE3': 3}. All-zero cohort: {'PHASE1': 10, 'PHASE2': 10, 'PHASE3': 6}.
- **Shared vs independent error.** 9/9 unanimous on the same wrong label.
- **Recall.** Mean S1 recall across these trials is 0.11; 6/9 had no model name the sponsor at all, i.e. the models are reasoning from priors, not memory.
- **Two failure modes, not one — split by endpoint type.** Of the 6 SUCCESS trials called FAILURE, 5 have a safety/tolerability primary endpoint; of the 3 FAILURE trials called SUCCESS, 0 do (baseline across all trials: 43/100, 43%). The models reason about whether the *drug works*, but a safety trial's registered bar is whether it was *tolerated* — a trial can clear that while the drug shows nothing. The mirror-image mode is an efficacy trial for a familiar mechanism, where the models assume the endpoint will be met and it is not. (Endpoint type is keyword-classified from `primary_endpoint`, so treat the counts as indicative.)
- **The shared errors are phase-prior errors.** Every one of these trials defies its phase's reputation: the phase-3 rows are FAILUREs the models called SUCCESS, and the phase-1/2 rows are SUCCESSes they called FAILURE. The models are not failing at random — they are failing exactly where the base rate points the wrong way.
- **Potentially mislabelled.** `NCT03033524`
